USA - 18 Mar `18Aclaris Therapeutics: ATI-50002

Official Title: A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo

In Brief: The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution, 0.46% in subjects with non-segmental facial vitiligo.

Detailed Description: This is a multicenter, open-label study designed to evaluate the safety, tolerability and efficacy of ATI-50002 Topical Solution 0.46% in subjects with non-segmental facial vitiligo. Subjects will be required to have a clinical diagnosis of non-segmental facial vitiligo effecting at least 0.25% of total body surface area (TBSA) (excluding upper and lower eyelids, mucosal lip areas, and forehead and chin areas covered by the stereotactic positioning device for photography) with at least one area of the face with normal pigmentation. Twenty-four eligible subjects will receive ATI-50002 Topical Solution, 0.46%, BID for 24 weeks.

Ages Eligible: 18 Years to 65 Years 

Start Date: March 19, 2018

Completion Date (estimated): September 30, 2019

Status: Active, not recruiting

Study ID from ClinicalTrials.gov: NCT03468855
Other Study ID Numbers: ATI-50002-VITI-201

Locations: USA

  • Encinitas, California
  • Los Angeles, California
  • Worcester, Massachusetts
  • Dallas, Texas
  • Lynchburg, Virginia

Contact: To learn more about this study, you or your doctor may contact Aclaris Therapeutics.

FAQOther Questions

  • How can I cure vitiligo?

    There is no cure for vitiligo, but there are a number of effective treatment options that can be discussed with your GP or dermatologist. The aim of treatment is to stop new pat...

  • What is vitiligo?

    Vitiligo (pronounced vit-ill-EYE-go) is a relatively common skin disease characterized by smooth, white, painless spots or patches on various parts of the body and hairs above i...

  • What causes vitiligo?

    Surprisingly, the causes of vitiligo are yet to be precisely established. Researchers know the cause is pre-wired in your genes, just waiting for a bad luck moment. In about hal...